Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Peterson

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
RMD Open|March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studiesPhilip J Mease, Joseph F Merola, Marina Magrey, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
RMD Open|April 7, 2025
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studiesPhilip J Mease, Lianne S Gensler, Ana-Maria Orbai, et al.
JCO Clinical Cancer Informatics|May 6, 2024
Assessment of <i>BRCA1</i> and <i>BRCA2</i> Germline Variant Data From Patients With Breast Cancer in a Real-World Data RegistryThales C Nepomuceno, Paulo Lyra, Jianbin Zhu, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Oncotarget|September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade gliomaCarl Koschmann, Daniel Zamler, Alan MacKay, et al.
Lancet (London, England)|May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trialsAlexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.
The Journal of Clinical Investigation|December 20, 2019
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemiaSzymon Klossowski, Hongzhi Miao, Katarzyna Kempinska, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
RMD Open|March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studiesPhilip J Mease, Joseph F Merola, Marina Magrey, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
RMD Open|April 7, 2025
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studiesPhilip J Mease, Lianne S Gensler, Ana-Maria Orbai, et al.
JCO Clinical Cancer Informatics|May 6, 2024
Assessment of <i>BRCA1</i> and <i>BRCA2</i> Germline Variant Data From Patients With Breast Cancer in a Real-World Data RegistryThales C Nepomuceno, Paulo Lyra, Jianbin Zhu, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Oncotarget|September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade gliomaCarl Koschmann, Daniel Zamler, Alan MacKay, et al.
Lancet (London, England)|May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trialsAlexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.
The Journal of Clinical Investigation|December 20, 2019
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemiaSzymon Klossowski, Hongzhi Miao, Katarzyna Kempinska, et al.
Pageof 3